At the 2016 annual meeting of the American Association for Cancer Research (AACR) one topic that attracted a lot of attention and debate was the use of mouse models to guide cancer immunotherapy drug development strategy.
Bernard A. Fox, PhD (pictured above) is Chief, Laboratory of Molecular and Tumor Immunology and holds the Harder Family Chair for Cancer Research at the Earle A. Chiles Research Institute at Providence Cancer Center. He’s also President and CEO of UbiVac.
You can follow him on Twitter at @BernardAFox.